What is SNOA's health score?

Sonoma Pharmaceuticals, Inc. (SNOA) has a TradeApes health score of 46 out of 100, rated Mixed. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is SNOA's estimated fair value?

Based on our 5-year discounted cash flow model, Sonoma Pharmaceuticals, Inc.'s estimated fair value is $N/A per share. This is a model estimate, not a price target or investment recommendation.

Is SNOA undervalued or overvalued?

Our model currently rates SNOA as Inconclusive. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for SNOA... Refresh in a moment for the full analysis.

Sonoma Pharmaceuticals, Inc. (SNOA)

Healthcare Inconclusive inconclusive mixed

$1.21

Updated: 2026-06-05

TradeApes Score

Financial Strength

35 Weak

Operating Trend

45 Mixed

Relative Value

60 Healthy

Capital Allocation

35 Weak

Risk

55 Mixed

Key Findings

+ Historically cheap — EV/EBITDA in bottom 25% of its 5-year range

Unlock Full Report →

− Weak interest coverage — earnings barely cover debt service

Unlock Full Report →

2 free score cards remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.